Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
10.84
-0.42 (-3.73%)
Oct 19, 2026, 3:46 PM EDT - Market open
Novavax Revenue
Novavax had revenue of $56.70M in the quarter ending June 30, 2026, a decrease of -76.30%. This brings the company's total for the last twelve months to $413.80M, down -61.64% year-over-year. In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. That makes Novavax the 12,334th largest company in the world by revenue and 2,418th in the United States.
Revenue (ttm)
$413.80M
Revenue Growth
-61.64%
P/S Ratio
4.42
Revenue / Employee
$552,465
Employees
749
Market Cap
1.79B
Revenue by Geography
- Rest of North America 575.67M 51.2%
- United States 405.61M 36.1%
- Rest of The World 126.46M 11.3%
- Europe 15.74M 1.4%
Fiscal year ended Dec 31, 2025 See the full Novavax breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12B | 441.32M | 64.69% |
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
| Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
| Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
| Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
| Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
| Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
| Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
| Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
| Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
| Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
| Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
| Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
| Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
| Dec 31, 2005 | 5.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.13B |
| Vir Biotechnology | 303.23M |
| Maravai LifeSciences Holdings | 208.78M |
| Agios Pharmaceuticals | 98.34M |
| Recursion Pharmaceuticals | 54.86M |
| Zymeworks | 37.13M |
| Immunome | 4.02M |
NVAX News
- 2 days ago - Novavax shareholder Shah Capital to step back from activist role - Reuters
- 3 days ago - Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather - Barrons
- 3 days ago - Novavax falls -11.9% - TheFly
- 3 days ago - Novavax falls -10.4% - TheFly
- 4 days ago - Novavax price target raised to $8 from $7 at Citi - TheFly
- 10 days ago - Novavax price target raised to $8 from $7 at BofA - TheFly
- 13 days ago - Novavax Stock (NVAX) Plunges After WHO Calms Plague Fears - TipRanks
- 5 weeks ago - Novavax Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts